{"prompt": "['APPENDIX 3: QUALITY OF LIFE - QLQ-C30', '80', 'APPENDIX 4: QUALITY OF LIFE - STO-22', '81', 'APPENDIX 5: ECOG PERFORMANCE STATUS - CALCULATION OF CLEARANCE', '82', 'APPENDIX 6 : RECIST CRITERIA, VERSION 1.1', '83', 'APPENDIX 7: IRECIST CRITERIA OF IMMUNOLOGICAL RESPONSE', '85', 'APPENDIX 8: ASSESSMENT OF TOXICITIES', '89', \"APPENDIX 9: SUMMARY OF CHARACTERISTICS PRODUCT AND INVESTIVATOR'S\", 'BROCHURE', '111', 'APPENDIX 10: AUTHORIZED AND PROHIBITED CONCOMITTANT MEDICATIONS', '112', 'APPENDIX 11: SERIOUS ADVERSE EVENT REPORT FORM', '114', 'APPENDIX 12: RULES FOR PUBLICATION FOR PRODIGE TRIALS', '118', 'APPENDIX 13: INSURANCE CERTIFICATE', '120', 'APPENDIX 14: APPROVAL OF THE IRB', '121', 'APPENDIX 15: ANSM AUTHORIZATION', '123', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 3 de 123']['LIST OF ABBREVIATIONS', 'Abbreviation or special', 'Explanation', 'term', 'AChE', 'Acetylcholine esterase', 'ADA', 'Anti-drug antibody', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'ALK', 'Anaplastic lymphoma kinase', 'ALT', 'Alanine aminotransferase', 'ANC', 'Absolute neutrophil count', 'APF12', 'Proportion of patients alive and progression free at 12 months from randomization', 'AST', 'Aspartate aminotransferase', 'AUC', 'Area under the curve', 'AUC0-28day', 'Area under the plasma drug concentration-time curve from time zero to Day', '28 post-dose', 'AUC5S', 'Area under the plasma drug concentration-time curve at steady state', 'BICR', 'Blinded Independent Central Review', 'BoR', 'Best objective response', 'BP', 'Blood pressure', 'C', 'Cycle', 'CBC', 'Complete blood count', 'CD', 'Cluster of differentiation', 'CI', 'Confidence interval', 'CL', 'Clearance', 'Cmax', 'Maximum plasma concentration', 'Cmax.ss', 'Maximum plasma concentration at steady state', 'CR', 'Complete response', 'CSA', 'Clinical study agreement', 'CSR', 'Clinical study report', 'CT', 'Computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Event', 'CTLA-4', 'Cytotoxic T-lymphocyte-associated antigen 4', 'Ctrough,ss', 'Trough concentration at steady state', 'CXCL', 'Chemokine (C-X-C motif) ligand', 'DoR', 'Duration of response', 'EC', 'Ethics Committee, synonymous to Institutional Review Board and Independent', 'Ethics Committee', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'Electronic case report form', 'EDoR', 'Expected duration of response', 'EGFR', 'Epidermal growth factor receptor', 'EU', 'European Union', 'FAS', 'Full analysis set', 'FDA', 'Food and Drug Administration', 'GCP', 'Good Clinical Practice', 'GI', 'Gastrointestinal', 'GMP', 'Good Manufacturing Practice', 'hCG', 'Human chorionic gonadotropin', 'HIV', 'Human immunodeficiency virus', 'HR', 'Hazard ratio', 'IB', \"Investigator's Brochure\", 'ICF', 'Informed consent form', 'ICH', 'International Conference on Harmonization', 'IDMC', 'Independent Data Monitoring Committee', 'IFN', 'Interferon', 'IgE', 'Immunoglobulin E', 'IgG', 'Immunoglobulin G', 'IHC', 'Immunohistochemistry', 'IL', 'Interleukin', 'ILD', 'Interstitial Lung Disease', 'ILS', 'Interstitial lung disease', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 4 de 123']['IM', 'Intramuscular', 'IMT', 'Immunomodulatory therapy', 'IP', 'Investigational product', 'irAE', 'Immune-related adverse event', 'IRB', 'Institutional Review Board', 'iRECIST', 'Immune-related Response Evaluation Criteria in Solid Tumors', 'ITT', 'Intent-to-Treat', 'IV', 'Intravenous', 'IVRS', 'Interactive Voice Response System', 'IWRS', 'Interactive Web Response System', 'LFT', 'Liver function tests', 'mAb', 'Monoclonal antibody', 'MDSC', 'Myeloid-derived suppressor cell', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MHLW', 'Minister of Health, Labor, and Welfare', 'miRNA', 'Micro-ribonucleic acid', 'MRI', 'Magnetic resonance imaging', 'NCI', 'National Cancer Institute', 'NE', 'Not evaluable', 'NSCLC', 'Non-small-cell lung cancer', 'OAE', 'Other significant adverse event', 'ORR', 'Objective response rate', 'os', 'Overall survival', 'PBMC', 'Peripheral blood mononuclear cell', 'PD', 'Progressive disease', 'PD-1', 'Programmed cell death 1', 'PD-L1', 'Programmed cell death ligand 1', 'PD-L2', 'Programmed cell death ligand 2', 'PDx', 'Pharmacodynamic(s)', 'PFS', 'Progression-free survival', 'PFS2', 'Time to second progression', 'PGx', 'Pharmacogenetic research', 'PJP', 'Pneumocystis jiroveci Pneumonia', 'PK', 'Pharmacokinetic(s)', 'PR', 'Partial response', 'QTcF', \"QT interval corrected for heart rate using Fridericia's formula\", 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors, version 1.1', 'RNA', 'Ribonucleic acid', 'RR', 'Response rate', 'RT-QPCR', 'Reverse transcription quantitative polymerase chain reaction', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SAS', 'Safety analysis set', 'SD', 'Stable disease', 'SNP', 'Single nucleotide polymorphism', 'SoC', 'Standard of Care', 'sPD-L1', 'Soluble programmed cell death ligand 1', 'T3', 'Triiodothyronine', 'T4', 'Thyroxine', 'TSH', 'Thyroid-stimulating hormone', 'TNF', 'Tumor necrosis factor', 'ULN', 'Upper limit of normal', 'US', 'United States', 'WBDC', 'Web-Based Data Capture', 'WHO', 'World Health Organization', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 5 de 123']\n\n###\n\n", "completion": "END"}